A novel self-assembling peptide for hemostasis during endoscopic submucosal dissection: a randomized controlled trial
Research output: Contribution to journal › Article › peer-review
Methods: This was a single-center randomized controlled trial of 101 patients undergoing ESD. Participants were randomized to a control group where diathermy was used to control bleeding or an interventional group where Purastat could be used. Follow-up endoscopy was performed at 4 weeks to assess wound healing.
Results: There was a significant reduction in the use of heat therapy for intraprocedural hemostasis in the interventional group compared with controls (49.3 % vs. 99.6 %, P < 0.001). There were no significant differences in the procedure length, time for hemostasis, and delayed bleeding rate between the groups. Complete wound healing at 4 weeks was noted in 48.8 % of patients in the interventional group compared with 25.0 % of controls (P = 0.02).
Conclusions: This study has demonstrated that Purastat is an effective hemostat that can reduce the need for heat therapy for bleeding during ESD. It may also have a role in improving post-resection wound healing.
|Number of pages||9|
|Early online date||17 Jul 2020|
|Publication status||Published - 1 Jan 2021|
- A novel self-assembling peptide for lemostasis
Rights statement: Subramaniam, S., Kandiah, K., Chedgy, F., Fogg, C., Thayalasekaran, S., Alkandari, A., & Bhandari, P. (2020). A novel self-assembling peptide for hemostasis during endoscopic submucosal dissection: a randomised controlled trial. Endoscopy. Ahead of print. © Georg Thieme Verlag KG. doi: 10.1055/a-1198-0558.
Accepted author manuscript (Post-print), 992 KB, PDF document
Due to publisher’s copyright restrictions, this document is not freely available to download from this website until: 17/07/21